On February 23, Atara announced an amendment to its Purchase and Sale Agreement with HealthCare Royalty Partners, deferring a $9 million cash milestone payment from 2026 to January 1, 2028, while issuing warrants in exchange. This eased immediate financial pressures amid low cash reserves post-January FDA rejection of EBVALLO. Traders extended the positive reaction into February 25 regular hours, with shares climbing from an open near prior close amid elevated volume, reflecting relief on runway extension for ongoing operations and potential regulatory resubmissions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.